A Combined Systemic Strategy for Overcoming Cisplatin Resistance in Head and Neck Cancer: From Target Identification to Drug Discovery

A Combined Systemic Strategy for Overcoming Cisplatin Resistance in Head and Neck Cancer: From Target Identification to Drug Discovery

Cisplatin is the first-line chemotherapy agent for head and neck cancer (HNC), but its therapeutic effects are hampered by its resistance. In this study, we employed systemic strategies to overcome cisplatin resistance (CR) in HNC. CR cells derived from isogenic HNC cell lines were generated. The CR...

Full description

Bibliographic Details
Main Authors: Yin-Ju Chen, Guo-Rung You, Meng-Yu Lai, Long-Sheng Lu, Chang-Yu Chen, Lai-Lei Ting, Hsin-Lun Lee, Yuzuka Kanno, Jeng-Fong Chiou, Ann-Joy Cheng
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Cancers
Subjects:
cisplatin resistance
head and neck cancer
SPC25
celastrol
mitotic division
transcriptome
Online Access:https://www.mdpi.com/2072-6694/12/11/3482

Internet

https://www.mdpi.com/2072-6694/12/11/3482

Similar Items